Why is the IDT (ASX:IDT) share price halted today?

Trading in the pharmaceutical manufacturer is on hold pending an announcement.

| More on:
a medical person in full protective clothing holds a tray of Covid-19 vaccinations amid a haze caused by cold and ice.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The IDT Australia Limited (ASX: IDT) share price is on ice today after the company requested a trading halt.

Before it was put on hold, the IDT share price was trading at 48 cents apiece.

IDT is a Melbourne-based pharmaceutical company involved in manufacturing mRNA for use in COVID-19 vaccines.

Why is the IDT share price halted?

IDT has been granted a trading halt pending an upcoming public announcement on mRNA vaccine production.

The company needs to consider its response to an announcement by the federal government on local mRNA manufacturing.

The company said it's not in a position to announce this to the market at present.

Early on Tuesday, the government revealed it has struck a deal with Moderna to build a new vaccine manufacturing facility in Victoria. At the time of writing, it's not clear if IDT will play any role in this deal.

IDT does not expect the trading halt to last more than two days and will make an announcement prior to this time.

What is the company working on?

As reported by Motley Fool Australia, IDT has reported it's successfully manufactured an mRNA drug product for use in a COVID-19 vaccine candidate.

On Monday, the company provided an update to investors on its mRNA manufacturing initiatives.

The company sees an unmet market need for commercial-scale manufacturing of mRNA.

IDT stated it wants to grow its mRNA facilities to become Australia's mRNA "manufacturing hub of excellence".

IDT share price snapshot

In the last 12 months, the IDT share price has sky rocketed 134% and has rallied 159% in the year to date.

Despite this, it's slipped 2% in the last month and 3% in the past week.

IDT has a market capitalisation of roughly $115 million based on the current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Guess which ASX healthcare stock is rocketing 110% on US product launch

Shareholders of this stock are smiling on Wednesday. Why is it rocketing?

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Own CSL shares? You're receiving a healthy dividend boost today!

The bank accounts of CSL shareholders are about to receive a healthy payment.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Blast off! Mesoblast share price surging 60%

Mesoblast shares are skyrocketing today.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL share price lower despite US FDA boost

The regulator has approved a treatment for sufferers of chronic kidney disease.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »